During the exhibition from March 10 to 13, Pharma Research showcased its company's strength via its flagship products - "Rejuran®" and "Conjuran®" DOT(TM) PN.

PharmaResearch (CEO Kim Thinkyou, Kang Ki-seok) participated in South Korea's largest international medical device hospital equipment exhibition called KIMES 2022, held at COEX in Seoul from March 10 to 13, showing off its status as original products manufacturer.

At this exhibition, PharmaResearch intensively showcased PN products such as Rejuran® and Conjuran® and clearly signified that it is an original company in Korea.

Rejuran® is a skin-rejuvenating medical device manufactured by applying PN (Polyucleotide), a regenerative substance derived from salmon, to DOT(TM) (DNA Optimizing Technology), a patent technology for Pharma Research, and has established itself as a representative skin booster in South Korea since its launch in 2014.

Conjuran® is also a medical device with DOT(TM) (DNA Optimizing Technology) patented technology that helps knee degenerative arthritis by reducing mechanical friction and relieving pain in the joint area.

An official from Pharma Research said, "Thank you for your interest and affection in this exhibition. We will strengthen our firm position in the market by collecting various feedback. We will definitely promote domestic and foreign buyers of the excellence and originality of DOT(TM)PDRN/DOT(TM)PN patent technology and accelerate overseas market expansion."

Meanwhile, PharmaResearch is a pharmaceutical company based on regenerative medicine that manufactures and do the marketing for pharmaceuticals, medical devices, cosmetics, and dietary supplement, focusing on tissue regeneration substances DOT(TM) PDRN and DOT(TM) PN. PharmaResearch's flagship brands are Rejuran, Conjuran, Rejuran Cosmetics, and Re-an eye drop.

Media Contact

Company Name: PharmaResearch

Contact Person: Seulki Kwak

Email: skkwak@pharmaresearch.co.kr

Phone: +82-31-8039-1422

Address:77-19, Gwahakdanji-ro

City: Gangneung-si

State: Gangwon-do

Country: South Korea

Website: http://pharmaresearch.co.kr/eng

Source: www.abnewswire.com

.

(C) 2022 M2 COMMUNICATIONS, source M2 PressWIRE